| Year |
Citation |
Score |
| 2020 |
Volkmann ER, Tashkin DP, Roth MD, Li N, Charles J, Mayes M, Kim G, Goldin J, Pourzand L, Clements PJ, Furst DE, Khanna D, Elashoff RM, Assassi S. The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. Seminars in Arthritis and Rheumatism. 50: 963-967. PMID 32906032 DOI: 10.1016/J.Semarthrit.2020.06.003 |
0.3 |
|
| 2019 |
Kim GHJ, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, Khanna D, Elashoff RM, Tseng CH, Roth MD, Goldin JG. Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease. Arthritis & Rheumatology (Hoboken, N.J.). PMID 31430058 DOI: 10.1002/Art.41085 |
0.319 |
|
| 2019 |
Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. The Journal of Rheumatology. PMID 30770517 DOI: 10.3899/Jrheum.180441 |
0.311 |
|
| 2018 |
Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, ... Elashoff RM, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of the Rheumatic Diseases. PMID 30409830 DOI: 10.1136/Annrheumdis-2018-213708 |
0.343 |
|
| 2018 |
Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, et al. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 123: 91-98. PMID 30089602 DOI: 10.1016/J.Lungcan.2018.06.013 |
0.322 |
|
| 2017 |
Shino MY, Weigt SS, Li N, Palchevskiy V, Derhovanessian A, Saggar R, Sayah DM, Huynh RH, Gregson AL, Fishbein MC, Ardehali A, Ross DJ, Lynch JP, Elashoff RM, Belperio JA. The prognostic importance of CXCR3 chemokine during organizing pneumonia on the risk of chronic lung allograft dysfunction after lung transplantation. Plos One. 12: e0180281. PMID 28686641 DOI: 10.1371/Journal.Pone.0180281 |
0.309 |
|
| 2017 |
Shino MY, Weigt SS, Li N, Derhovanessian A, Sayah DM, Saggar R, Huynh RH, Gregson AL, Ardehali A, Ross DJ, Lynch JP, Elashoff RM, Belperio JA. The prognostic importance of bronchoalveolar lavage fluid CXCL9 during minimal acute rejection on the risk of chronic lung allograft dysfunction. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 28637080 DOI: 10.1111/Ajt.14397 |
0.303 |
|
| 2017 |
Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM. Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis & Rheumatology (Hoboken, N.J.). PMID 28376288 DOI: 10.1002/Art.40114 |
0.319 |
|
| 2017 |
Volkmann E, Sim M, Tashkin D, Khanna D, Clements P, Roth M, Furst D, Pickney A, Goldmuntz E, Keyes-Elstein L, Elashoff R, Sullivan K. OP0124 Treatment with cyclophosphamide for systemic sclerosis-related interstitial lung disease does not improve survival after 12 years of follow up Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2017-Eular.2488 |
0.325 |
|
| 2016 |
Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Research & Therapy. 18: 305. PMID 28038680 DOI: 10.1186/S13075-016-1203-Y |
0.345 |
|
| 2016 |
Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease (SSc-ILD): Results of Scleroderma Lung Study II. Chest. PMID 28012804 DOI: 10.1016/J.Chest.2016.11.052 |
0.315 |
|
| 2016 |
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, ... ... Elashoff RM, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. The Lancet. Respiratory Medicine. PMID 27469583 DOI: 10.1016/S2213-2600(16)30152-7 |
0.342 |
|
| 2016 |
Kim HJ, Tashkin DP, Gjertson DW, Brown MS, Kleerup E, Chong S, Belperio JA, Roth MD, Abtin F, Elashoff R, Tseng CH, Khanna D, Goldin JG. Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. Annals of the Rheumatic Diseases. PMID 26757749 DOI: 10.1136/Annrheumdis-2015-208929 |
0.323 |
|
| 2016 |
Hoffmann-Vold A, Huynh R, Volkmann E, Palchevskiy S, Midtvedt Ø, Garen T, Der Hovanessian A, Weigt S, Fishbein M, Ardehali A, Ross D, Saggar R, Lynch J, Aukrust P, Ueland T, ... Elashoff R, et al. FRI0257 Augmented Concentrations of Cx3cl1 Are Associated with Progressiv Interstitial Lung Disease in Systemic Sclerosis Annals of the Rheumatic Diseases. 75: 527.1-527. DOI: 10.1136/Annrheumdis-2016-Eular.4406 |
0.344 |
|
| 2016 |
Volkmann E, Tashkin D, Elashoff R, Tseng C-, Khanna D, Mayes M, Charles J, Clements P, Roth M, Furst D, Assassi S. FRI0275 Change in CXCL4 Levels May Predict Treatment Response in Systemic Sclerosis-Related Interstitial Lung Disease (SSC-ILD) Annals of the Rheumatic Diseases. 75: 535-535. DOI: 10.1136/Annrheumdis-2016-Eular.3799 |
0.313 |
|
| 2016 |
Volkmann E, Tashkin D, Fischer A, Hoffmann-Vold A-, Tseng C-, LeClair H, Khanna D, Clements P, Roth M, Elashoff R. FRI0274 Predictors of Survival in Patients with Systemic Sclerosis-Related Interstitial Lung Disease Enrolled in The Scleroderma Lung Study II Annals of the Rheumatic Diseases. 75: 534-534. DOI: 10.1136/Annrheumdis-2016-Eular.2999 |
0.355 |
|
| 2016 |
Khanna D, Roth M, Clements P, Furst D, Tseng C-, Elashoff R, Volkmann E, Kafaja S, Goldin J, Tashkin D. FRI0267 Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease: Scleroderma Lung Study II Annals of the Rheumatic Diseases. 75: 531-531. DOI: 10.1136/Annrheumdis-2016-Eular.2126 |
0.388 |
|
| 2016 |
Khanna D, Tashkin D, Furst DE, Tseng C-, Wilhalme H, Roth M, Kafaja S, Volkmann E, Elashoff R, Clements P. FRI0252 Efficacy of Mycophenolate Mofetil (MMF) versus Oral Cyclophosphamide (CYC) on Skin Thickness in The Scleroderma Lung Study II Annals of the Rheumatic Diseases. 75: 525-525. DOI: 10.1136/Annrheumdis-2016-Eular.2123 |
0.311 |
|
| 2016 |
Tashkin D, Volkmann E, Khanna D, Roth M, Theodore A, Wang B, Tseng C, Elashoff R. Frequent Cough in Scleroderma-Related Interstitial Lung Disesae (SSc-ILD): Characterisitcs and Response to Potentially Disease-Modifying Therapy in a Randomized Controlled Trial (RCT) (Scleroderma Lung Study II) Chest. 150: 473A. DOI: 10.1016/J.Chest.2016.08.487 |
0.331 |
|
| 2015 |
Garon EB, Abarca PA, Strunck JL, Nameth D, Neumann C, Wolf B, Kim KY, Marx C, Elashoff RM. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. Critical Reviews in Oncogenesis. 20: 339-47. PMID 27279233 DOI: 10.1615/Critrevoncog.V20.I5-6.70 |
0.318 |
|
| 2015 |
Faries MB, Cochran AJ, Elashoff RM, Thompson JF. Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report'. The British Journal of Dermatology. 172: 571-3. PMID 25776247 DOI: 10.1111/Bjd.13676 |
0.302 |
|
| 2015 |
Tashkin D, Roth M, Clements P, Furst D, Khanna D, Goldin J, Kleerup E, Arriola E, Tseng C, Elashoff R. Efficacy and Safety of Mycophenolate (MMF) Vs Oral Cyclophosphamide (CYC) for Treatment of Scleroderma-Interstitial Lung Disease (Ssc-ILD): Results of Scleroderma Lung Study II Chest. 148: 637A. DOI: 10.1378/Chest.2331164 |
0.31 |
|
| 2015 |
Volkmann E, Tashkin D, Clements P, Roth M, Furst D, Khanna D, Tseng C, Arriola E, Elashoff R. SAT0444 Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease Annals of the Rheumatic Diseases. 74: 821.2-821. DOI: 10.1136/Annrheumdis-2015-Eular.2081 |
0.35 |
|
| 2014 |
Tashkin DP, Volkmann ER, Tseng CH, Kim HJ, Goldin J, Clements P, Furst D, Khanna D, Kleerup E, Roth MD, Elashoff R. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Annals of the Rheumatic Diseases. PMID 25452309 DOI: 10.1136/Annrheumdis-2014-206076 |
0.353 |
|
| 2014 |
Volkmann ER, Saggar R, Khanna D, Torres B, Flora A, Yoder L, Clements PJ, Elashoff RM, Ross DJ, Agrawal H, Borazan N, Furst DE, Saggar R. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis & Rheumatology (Hoboken, N.J.). 66: 1900-8. PMID 24729406 DOI: 10.1002/Art.38623 |
0.315 |
|
| 2014 |
Volkmann E, Li N, Tashkin D, Furst D, Elashoff R. OP0275 Development of A Composite Outcome Measure for Systemic Sclerosis-Related Interstitial Lung Disease Annals of the Rheumatic Diseases. 73: 165.3-165. DOI: 10.1136/Annrheumdis-2014-Eular.2068 |
0.32 |
|
| 2013 |
Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli B, Elashoff R. Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD Respiratory Medicine. 107: 1904-1911. PMID 23972968 DOI: 10.1016/J.Rmed.2013.08.001 |
0.329 |
|
| 2013 |
Garon EB, Siegfried JM, Dubinett SM, Elashoff RM, Park DJ, Parikh RJ, Patel R, Hu EH, Reckamp KL, Adams B, Martinez D, Wang H, Kabbinavar F, Dacic S, Brennan M, et al. Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). Cancer Research. 73: 4664-4664. DOI: 10.1158/1538-7445.Am2013-4664 |
0.303 |
|
| 2013 |
Khanna D, Roth M, Furst D, Clements P, Goldin J, Arriola E, Kotlerman J, Tseng C-, Kim G, Elashoff R, Tashkin D. FRI0396 Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (scleroderma lung study [SLS] II): rationale, design, methods, baseline characteristics and patient disposition Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.1523 |
0.366 |
|
| 2013 |
Weigt S, Wang X, Numnez S, Derhovanessian A, Shino M, Gregson A, Lynch III J, Saggar R, Ross D, Ardehali A, Elashoff R, Belperio J. YKL-40 Production Is Increased in the Lung during Aspergillus Colonization and BOS after Lung Transplantation The Journal of Heart and Lung Transplantation. 32: S220-S221. DOI: 10.1016/J.Healun.2013.01.557 |
0.321 |
|
| 2012 |
Elashoff RM, Li G, Zhou Y. Nonparametric inference for assessing treatment efficacy in randomized clinical trials with a time-to-event outcome and all-or-none compliance. Biometrika. 99: 393-404. PMID 23843664 DOI: 10.1093/Biomet/Ass004 |
0.301 |
|
| 2012 |
Tashkin DP, Wang HJ, Halpin D, Kleerup EC, Connett J, Li N, Elashoff R. Comparison of the variability of the annual rates of change in FEV₁ determined from serial measurements of the pre- versus post-bronchodilator FEV₁ over 5 years in mild to moderate COPD: results of the lung health study. Respiratory Research. 13: 70. PMID 22894725 DOI: 10.1186/1465-9921-13-70 |
0.302 |
|
| 2012 |
Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. 142: 614-21. PMID 22156609 DOI: 10.1378/Chest.11-0801 |
0.341 |
|
| 2012 |
Morton DL, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, Conti RCD, Lee JE, Huth JF, Faries MB, Dalgleish AG, Wagner JD, Hersh E, Schneebaum S, Anderson CM, Smithers M, ... ... Elashoff R, et al. Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases Journal of Clinical Oncology. 30: 8534-8534. DOI: 10.1200/Jco.2012.30.15_Suppl.8534 |
0.333 |
|
| 2011 |
Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, Strollo DC, Kleerup E, Chong D, Shah SK, Ahmad S, Abtin F, Tashkin DP, Goldin JG. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. European Radiology. 21: 2455-65. PMID 21927793 DOI: 10.1007/S00330-011-2223-2 |
0.324 |
|
| 2011 |
Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prevention Research (Philadelphia, Pa.). 4: 984-93. PMID 21733822 DOI: 10.1158/1940-6207.Capr-11-0078 |
0.348 |
|
| 2011 |
Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, Saggar R, Tashkin DP. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis and Rheumatism. 63: 3078-85. PMID 21618205 DOI: 10.1002/Art.30467 |
0.347 |
|
| 2011 |
Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis and Rheumatism. 63: 2797-808. PMID 21547897 DOI: 10.1002/Art.30438 |
0.335 |
|
| 2011 |
Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, Khanna D, Li N, Elashoff R, Schraufnagel DE. Adverse events during the Scleroderma Lung Study. The American Journal of Medicine. 124: 459-67. PMID 21531236 DOI: 10.1016/J.Amjmed.2010.12.009 |
0.323 |
|
| 2011 |
Altstein LL, Li G, Elashoff RM. A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial. Statistics in Medicine. 30: 709-17. PMID 21394747 DOI: 10.1002/Sim.4131 |
0.308 |
|
| 2011 |
Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, ... ... Elashoff R, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 142-8. PMID 21135282 DOI: 10.1200/Jco.2010.30.2729 |
0.33 |
|
| 2010 |
Au K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, Tashkin D, Roth MD, Elashoff R, Furst DE. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care & Research. 62: 1772-8. PMID 20740615 DOI: 10.1002/Acr.20320 |
0.35 |
|
| 2009 |
Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, Roth MD, Clements P, Furst DE, Khanna D, Vasunilashorn S, Li G, Tashkin DP. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 136: 1333-40. PMID 19892673 DOI: 10.1378/Chest.09-0108 |
0.35 |
|
| 2009 |
Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Rheumatology (Oxford, England). 48: 1537-40. PMID 19776222 DOI: 10.1093/Rheumatology/Kep284 |
0.322 |
|
| 2009 |
Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. Bmc Cancer. 9: 213. PMID 19563666 DOI: 10.1186/1471-2407-9-213 |
0.317 |
|
| 2009 |
Weigt SS, Elashoff RM, Huang C, Ardehali A, Gregson AL, Kubak B, Fishbein MC, Saggar R, Keane MP, Saggar R, Lynch JP, Zisman DA, Ross DJ, Belperio JA. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 9: 1903-11. PMID 19459819 DOI: 10.1111/J.1600-6143.2009.02635.X |
0.307 |
|
| 2009 |
Busuttil A, Weigt SS, Keane MP, Xue YY, Palchevskiy V, Burdick MD, Huang C, Zisman DA, Fishbein M, Lynch JP, Strieter RM, Elashoff RM, Belperio JA. CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. The European Respiratory Journal. 34: 676-86. PMID 19386686 DOI: 10.1183/09031936.00157508 |
0.305 |
|
| 2009 |
Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 72: 1217-22. PMID 19349600 DOI: 10.1212/01.Wnl.0000345668.03039.90 |
0.306 |
|
| 2009 |
Hant FN, Ludwicka-Bradley A, Wang H, Li N, Elashoff R, Tashkin DP, Silver RM. Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma The Journal of Rheumatology. 36: 773-780. PMID 19286849 DOI: 10.3899/Jrheum.080633 |
0.311 |
|
| 2008 |
Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 134: 358-67. PMID 18641099 DOI: 10.1378/Chest.07-2444 |
0.308 |
|
| 2008 |
Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, Ardehali A, Gregson AL, Kubak B, Fishbein MC, Saggar R, Ross DJ, Lynch JP, Zisman DA, Belperio JA. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 8: 1512-22. PMID 18513272 DOI: 10.1111/J.1600-6143.2008.02280.X |
0.312 |
|
| 2008 |
Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. American Journal of Respiratory and Critical Care Medicine. 177: 91-8. PMID 17901414 DOI: 10.1164/Rccm.200705-655Oc |
0.305 |
|
| 2008 |
Chlebowski RT, Blackburn GL, Hoy MK, Thomson CA, Giuliano AE, McAndrew P, Hudis CA, Butler J, Shapiro A, Elashoff RM, Study WIN. Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome Journal of Clinical Oncology. 26: 522-522. DOI: 10.1200/Jco.2008.26.15_Suppl.522 |
0.311 |
|
| 2007 |
Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. American Journal of Respiratory and Critical Care Medicine. 176: 1026-34. PMID 17717203 DOI: 10.1164/Rccm.200702-326Oc |
0.353 |
|
| 2007 |
Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Annals of the Rheumatic Diseases. 66: 1641-7. PMID 17485423 DOI: 10.1136/Ard.2007.069518 |
0.309 |
|
| 2007 |
Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, Schneebaum S, Schuchter L, Gammon G, Elashoff R. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites Journal of Clinical Oncology. 25: 8508-8508. DOI: 10.1200/Jco.2007.25.18_Suppl.8508 |
0.33 |
|
| 2006 |
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. The New England Journal of Medicine. 354: 2655-66. PMID 16790698 DOI: 10.1056/Nejmoa055120 |
0.333 |
|
| 2006 |
Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3381-8. PMID 16740761 DOI: 10.1158/1078-0432.Ccr-06-0112 |
0.315 |
|
| 2005 |
Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis and Rheumatism. 52: 592-600. PMID 15692967 DOI: 10.1002/Art.20787 |
0.307 |
|
| 2004 |
Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, Roth MD. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis and Rheumatism. 50: 1909-17. PMID 15188367 DOI: 10.1002/Art.20265 |
0.308 |
|
| 2004 |
Taback B, O'Day SJ, Boasberg PD, Shu S, Fournier P, Elashoff R, Wang HJ, Hoon DS. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. Journal of the National Cancer Institute. 96: 152-6. PMID 14734706 DOI: 10.1093/Jnci/Djh011 |
0.308 |
|
| 2003 |
Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang HJ, Gerami M, Hoon DS. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2558-63. PMID 12829676 DOI: 10.1200/Jco.2003.06.110 |
0.31 |
|
| 1994 |
Wanek LA, Elashoff RM, Goradia TM, Morton DL, Cochran AJ. Application of multistage Markov modeling to malignant melanoma progression Cancer. 73: 336-343. PMID 8293397 DOI: 10.1002/1097-0142(19940115)73:2<336::Aid-Cncr2820730217>3.0.Co;2-W |
0.302 |
|
| 1993 |
Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL. Malignant Melanoma: Effects of an Early Structured Psychiatric Intervention, Coping, and Affective State on Recurrence and Survival 6 Years Later Archives of General Psychiatry. 50: 681-689. PMID 8357293 DOI: 10.1001/Archpsyc.1993.01820210015002 |
0.32 |
|
| 1992 |
Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Annals of Surgery. 216: 463-82. PMID 1417196 DOI: 10.1097/00000658-199210000-00010 |
0.308 |
|
| 1992 |
Maliakkal RJ, Blackburn GL, Willcutts HD, Williams M, Levin R, Willcutts HD, Elashoff R. Optimal design of clinical outcome studies in nutrition and cancer: future directions. Journal of Parenteral and Enteral Nutrition. 16. PMID 1287222 DOI: 10.1177/014860719201600614 |
0.314 |
|
| 1990 |
Chlebowski RT, Bulcavage L, Grosvenor M, Oktay E, Block JB, Chlebowski JS, Ali I, Elashoff R. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. Journal of Clinical Oncology. 8: 9-15. PMID 1688616 DOI: 10.1200/Jco.1990.8.1.9 |
0.362 |
|
| 1988 |
Gail MH, Muenz L, McIntire KR, Radovich B, Braunstein G, Brown PR, Deftos L, Dnistrian A, Dunsmore M, Elashoff R, Geller N, Go VLW, Hirji K, Klauber MR, Pee D, et al. Multiple Markers for Lung Cancer Diagnosis: Validation of Models for Advanced Lung Cancer Journal of the National Cancer Institute. 76: 805-816. PMID 3343691 DOI: 10.1093/Jnci/80.2.97 |
0.331 |
|
| 1987 |
Ganz PA, Ma PY, Wang HJ, Elashoff RM. Evaluation of three biochemical markers for serially monitoring the therapy of small-cell lung cancer Journal of Clinical Oncology. 5: 472-479. PMID 3029340 DOI: 10.1200/Jco.1987.5.3.472 |
0.321 |
|
| 1982 |
Callery C, Cochran AJ, Roe DJ, Rees W, Nathanson SD, Benedetti JK, Elashoff RM, Morton DL. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes Annals of Surgery. 196: 69-75. PMID 7092355 DOI: 10.1097/00000658-198207000-00015 |
0.301 |
|
| Show low-probability matches. |